Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the price ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The company’s shares closed ...

Lockheed Martin Just Lost a Multibillion-Dollar Deal -- but All Hope Is Not Lost was originally published by The Motley Fool ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...

Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and ...

While the team took on Europe's biggest space companies, a slice of Gruyère cheese almost derailed their ambitious mission.

With $274 billion in revenue last year and $3.3 trillion in assets under management, JPMorgan Chase has more resources than ...

Welcome to Edition 7.17 of the Rocket Report! Next week marks 10 years since one of the more spectacular launch failures of this century. On October 28, 2014, an Antares rocket, then operated by ...

CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or ...

Mirae Asset Global Investments Co. Ltd. raised its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 21.5% during the third quarter, according to its most recent filing with the ...